NEW YORK, February 6, 2017 /PRNewswire/ --
Stock-Callers.com today revisits the Biotechnology space to take a closerlook at the performances of select equities: Amgen Inc. (NASDAQ: AMGN), Array BioPharma Inc. (NASDAQ: ARRY), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). These companies are part of the Healthcare sector,
Thousand Oaks, California headquartered Amgen Inc.'s stock finished last Friday's session 4.98% higher at $167.53. A total volume of 7.36 million shares was traded, which was above their three months average volume of 3.88 million shares. The Company's shares have advanced 9.59% in the past month, 21.60% in the previous three months, and 14.58% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 11.65% and 6.81%, respectively. Additionally, shares of Amgen, which discovers, develops, manufactures, and delivers human therapeutics worldwide, have a Relative Strength Index (RSI) of 72.53.
On February 01st, 2017, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On February 03rd, 2017, Amgen announced the appointment of Charles M. Holley Jr. to its Board of Directors. Mr. Holley, 60, is the former Executive Vice President and Chief Financial Officer for Wal-Mart Stores, Inc., where he served from 2010 to 2015 and as Executive Vice President between January 01st, 2016, and January 31st, 2016. See our free and comprehensive research report on AMGN at:
On Friday, shares in Boulder, Colorado headquartered Array BioPharma Inc. ended the session 1.01% lower at $10.76. The stock recorded a trading volume of 3.95 million shares. The Company's shares have gained 17.34% in the last one month, 84.25% in the previous three months, and 22.41% on an YTD basis. The stock is trading 15.46% above its 50-day moving average and 94.16% above its 200-day moving average. Moreover, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia/Pacific, have an RSI of 58.04.
On February 02nd, 2017, Array BioPharma announced that it will report financial results for Q2 FY17 on February 09th, 2017. The Company will hold a conference call to discuss those results on February 09th, 2017 at 9:00 am ET.
On February 03rd, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $8 a share to $13 a share. ARRY free research report PDF is just a click away at:
Cambridge, Massachusetts headquartered Merrimack Pharmaceuticals Inc.'s shares rose 2.95%, closing the session at $3.14 with a total trading volume of 1.38 million shares. The stock is trading 28.26% below its 50-day moving average. Shares of the Company, which engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the US, have an RSI of 35.45.
On January 18th, 2017, Merrimack Pharmaceuticals announced that Richard Peters, M.D., Ph.D., has been appointed as the Company's President and CEO, effective February 06th, 2017. Dr. Peters will join Merrimack from his current role at Sanofi Genzyme, where he serves as Senior Vice President and Head of Global Rare Diseases. He replaces Gary Crocker, Chairman, Interim President, and CEO, who guided the Company during the recent restructuring process and search for a permanent CEO. Mr. Crocker will remain Chairman of the Board. Sign up for your complimentary report on MACK at:
Last Friday at the close, shares in New Haven, Connecticut headquartered Alexion Pharmaceuticals Inc. recorded a trading volume of 3.03 million shares. The stock ended the session 1.09% lower at $126.98. The Company's shares have advanced 3.78% since the start of this year. The stock is trading above its 50-day moving average by 0.31%. Furthermore, shares of Alexion Pharma, which develops and commercializes life-transforming therapeutic products, have an RSI of 43.99.
On January 09th, 2017, Alexion Pharma announced that it has submitted marketing applications to the US Food and Drug Administration and the European Medicines Agency (EMA) to extend the indication for Soliris® (eculizumab) as a treatment for patients with refractory generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. The Company stated that The European submission has been validated by the EMA, marking the beginning of the review process in Europe for this potential new indication for Soliris. Register for free on Stock-Callers.com and download the latest research report on ALXN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All